메뉴 건너뛰기




Volumn 14, Issue 1, 2016, Pages

Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting

Author keywords

Atrial fibrillation; Chromogenic anti factor IIa; Dabigatran; Geriatric; HPLC MS MS

Indexed keywords

CREATININE; CYSTATIN C; DABIGATRAN ETEXILATE;

EID: 84965050758     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-016-0084-2     Document Type: Article
Times cited : (12)

References (63)
  • 1
    • 77449106972 scopus 로고    scopus 로고
    • At last, a RE-LYable alternative to warfarin for atrial fibrillation
    • Hankey GJ. At last, a RE-LYable alternative to warfarin for atrial fibrillation. Int J Stroke. 2009;4(6):454-5. doi: 10.1111/j.1747-4949.2009.00389.x.
    • (2009) Int J Stroke , vol.4 , Issue.6 , pp. 454-455
    • Hankey, G.J.1
  • 2
    • 79954456496 scopus 로고    scopus 로고
    • Dabigatran etexilate: a new oral thrombin inhibitor
    • Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436-50. doi: 10.1161/CIRCULATIONAHA.110.004424.
    • (2011) Circulation , vol.123 , Issue.13 , pp. 1436-1450
    • Hankey, G.J.1    Eikelboom, J.W.2
  • 3
    • 84904675268 scopus 로고    scopus 로고
    • Dabigatran, bleeding, and the regulators
    • Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ. 2014;349:g4517. http://dx.doi.org/10.1136/bmj.g4517.
    • (2014) BMJ. , vol.349 , pp. g4517
    • Moore, T.J.1    Cohen, M.R.2    Mattison, D.R.3
  • 4
    • 84893160985 scopus 로고    scopus 로고
    • The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
    • Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104.
    • (2014) J Am Coll Cardiol , vol.63 , Issue.4 , pp. 321-328
    • Reilly, P.A.1    Lehr, T.2    Haertter, S.3    Connolly, S.J.4    Yusuf, S.5    Eikelboom, J.W.6
  • 5
    • 84881221868 scopus 로고    scopus 로고
    • Dabigatran: is there a role for coagulation assays in guiding therapy?
    • Brunetti L, Bandali F. Dabigatran: is there a role for coagulation assays in guiding therapy? Ann Pharmacother. 2013;47(6):828-40. doi: 10.1345/aph.1R720.
    • (2013) Ann Pharmacother , vol.47 , Issue.6 , pp. 828-840
    • Brunetti, L.1    Bandali, F.2
  • 6
    • 84857853180 scopus 로고    scopus 로고
    • Bleeding risk with dabigatran in the frail elderly
    • Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864-6. doi: 10.1056/NEJMc1112874.
    • (2012) N Engl J Med , vol.366 , Issue.9 , pp. 864-866
    • Harper, P.1    Young, L.2    Merriman, E.3
  • 8
    • 84945532654 scopus 로고    scopus 로고
    • The case for dosing dabigatran: how tailoring dose to patient renal function, weight, and age could improve the benefit-risk ratio
    • Safouris A, Triantafyllou N, Parissis J, Tsivgoulis. The case for dosing dabigatran: how tailoring dose to patient renal function, weight, and age could improve the benefit-risk ratio. Ther Adv Neurol Disord. 2015;8(6):245-54. doi: 10.1177/1756285615601360.
    • (2015) Ther Adv Neurol Disord. , vol.8 , Issue.6 , pp. 245-254
    • Safouris, A.1    Triantafyllou, N.2    Parissis, J.3    Tsivgoulis4
  • 9
    • 81855169531 scopus 로고    scopus 로고
    • Acutely injured patients on dabigatran
    • Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011;365(21):2039-40. doi: 10.1056/NEJMc1111095.
    • (2011) N Engl J Med , vol.365 , Issue.21 , pp. 2039-2040
    • Cotton, B.A.1    McCarthy, J.J.2    Holcomb, J.B.3
  • 10
    • 84883259388 scopus 로고    scopus 로고
    • Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation
    • Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042.
    • (2013) J Am Coll Cardiol , vol.62 , Issue.10 , pp. 900-908
    • Eikelboom, J.W.1    Connolly, S.J.2    Hart, R.G.3    Wallentin, L.4    Reilly, P.5    Oldgren, J.6
  • 11
    • 79958126202 scopus 로고    scopus 로고
    • Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    • Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747.
    • (2011) Circulation , vol.123 , Issue.21 , pp. 2363-2372
    • Eikelboom, J.W.1    Wallentin, L.2    Connolly, S.J.3    Ezekowitz, M.4    Healey, J.S.5    Oldgren, J.6
  • 12
    • 84863660210 scopus 로고    scopus 로고
    • Dabigatran: uncharted waters and potential harms
    • Radecki RP. Dabigatran: uncharted waters and potential harms. Ann Intern Med. 2012;157(1):66-8. doi: 10.7326/0003-4819-157-1-201207030-00467.
    • (2012) Ann Intern Med , vol.157 , Issue.1 , pp. 66-68
    • Radecki, R.P.1
  • 13
    • 84857077970 scopus 로고    scopus 로고
    • Bleeding with dabigatran (Pradaxa)
    • Anonymous. Bleeding with dabigatran (Pradaxa). Med Lett Drugs Ther. 2011;53(1379-1380):98.
    • (2011) Med Lett Drugs Ther. , vol.53 , Issue.1379-1380 , pp. 98
  • 14
    • 84864350306 scopus 로고    scopus 로고
    • Hemopericardium in a patient treated with dabigatran etexilate
    • Barton CA, McMillian WD, Sadi Raza S, Keller RE. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy. 2012;32(5):e103-7. doi: 10.1002/j.1875-9114.2012.01036.x.
    • (2012) Pharmacotherapy , vol.32 , Issue.5 , pp. e103-e107
    • Barton, C.A.1    McMillian, W.D.2    Sadi Raza, S.3    Keller, R.E.4
  • 15
    • 84862243930 scopus 로고    scopus 로고
    • Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients
    • Bene J, Said W, Rannou M, Deheul S, Coupe P, Gautier S. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother. 2012;46(6), e14. doi: 10.1345/aph.1Q705.
    • (2012) Ann Pharmacother , vol.46 , Issue.6
    • Bene, J.1    Said, W.2    Rannou, M.3    Deheul, S.4    Coupe, P.5    Gautier, S.6
  • 16
    • 84859549864 scopus 로고    scopus 로고
    • Clinical challenges in a patient with dabigatran-induced fatal hemorrhage
    • Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012;10(2):160-3. doi: 10.1016/j.amjopharm.2012.02.004.
    • (2012) Am J Geriatr Pharmacother , vol.10 , Issue.2 , pp. 160-163
    • Cano, E.L.1    Miyares, M.A.2
  • 17
    • 84865045736 scopus 로고    scopus 로고
    • Fatal gastrointestinal hemorrhage after a single dose of dabigatran
    • Kernan L, Ito S, Shirazi F, Boesen K. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila). 2012;50(7):571-3. doi: 10.3109/15563650.2012.705290.
    • (2012) Clin Toxicol (Phila) , vol.50 , Issue.7 , pp. 571-573
    • Kernan, L.1    Ito, S.2    Shirazi, F.3    Boesen, K.4
  • 18
    • 84865815830 scopus 로고    scopus 로고
    • Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation
    • Lillo-Le Louet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost. 2012;108(3):583-5. doi: 10.1160/TH12-03-0149.
    • (2012) Thromb Haemost , vol.108 , Issue.3 , pp. 583-585
    • Lillo-Le Louet, A.1    Wolf, M.2    Soufir, L.3    Galbois, A.4    Dumenil, A.S.5    Offenstadt, G.6
  • 20
    • 84859800192 scopus 로고    scopus 로고
    • Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment
    • Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol. 2012;52(1 Suppl):119S-25S. doi: 10.1177/0091270011415527.
    • (2012) J Clin Pharmacol , vol.52 , Issue.1 , pp. 119S-125S
    • Hariharan, S.1    Madabushi, R.2
  • 21
    • 84866008554 scopus 로고    scopus 로고
    • Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation
    • Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol. 2011. doi: 10.1177/0091270011417716.
    • (2011) J Clin Pharmacol
    • Lehr, T.1    Haertter, S.2    Liesenfeld, K.H.3    Staab, A.4    Clemens, A.5    Reilly, P.A.6
  • 22
    • 80055122488 scopus 로고    scopus 로고
    • Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
    • Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-75. doi: 10.1111/j.1538-7836.2011.04498.x.
    • (2011) J Thromb Haemost , vol.9 , Issue.11 , pp. 2168-2175
    • Liesenfeld, K.H.1    Lehr, T.2    Dansirikul, C.3    Reilly, P.A.4    Connolly, S.J.5    Ezekowitz, M.D.6
  • 23
    • 84864288063 scopus 로고    scopus 로고
    • The food and drug administration decision not to approve the 110 mg dose of dabigatran: give us a way out
    • Kowey PR, Naccarelli GV. The food and drug administration decision not to approve the 110 mg dose of dabigatran: give us a way out. Am J Med. 2012;125(8):732. doi: 10.1016/j.amjmed.2011.10.035.
    • (2012) Am J Med , vol.125 , Issue.8 , pp. 732
    • Kowey, P.R.1    Naccarelli, G.V.2
  • 24
    • 84965040095 scopus 로고    scopus 로고
    • Pradaxa® European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
  • 25
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    • van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-27. doi: 10.1160/TH09-11-0758.
    • (2010) Thromb Haemost , vol.103 , Issue.6 , pp. 1116-1127
    • Ryn, J.1    Stangier, J.2    Haertter, S.3    Liesenfeld, K.H.4    Wienen, W.5    Feuring, M.6
  • 26
    • 79959782689 scopus 로고    scopus 로고
    • An assay to monitor bivalirudin levels on cardiopulmonary bypass
    • Salemi A, Agrawal YP, Fontes MA. An assay to monitor bivalirudin levels on cardiopulmonary bypass. Ann Thorac Surg. 2011;92(1):332-4. doi: 10.1016/j.athoracsur.2010.12.064.
    • (2011) Ann Thorac Surg , vol.92 , Issue.1 , pp. 332-334
    • Salemi, A.1    Agrawal, Y.P.2    Fontes, M.A.3
  • 27
    • 77952552934 scopus 로고    scopus 로고
    • Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant
    • Salmela B, Joutsi-Korhonen L, Saarela E, Lassila R. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant. Thromb Res. 2010;125(6):538-44. doi: 10.1016/j.thromres.2010.02.002.
    • (2010) Thromb Res , vol.125 , Issue.6 , pp. 538-544
    • Salmela, B.1    Joutsi-Korhonen, L.2    Saarela, E.3    Lassila, R.4
  • 28
    • 84871744380 scopus 로고    scopus 로고
    • The effect of dabigatran on select specialty coagulation assays
    • Adcock DM, Gosselin R, Kitchen S, Dwyre DM. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol. 2013;139(1):102-9. doi: 10.1309/AJCPY6G6ZITVKPVH139/1/102.
    • (2013) Am J Clin Pathol , vol.139 , Issue.1 , pp. 102-109
    • Adcock, D.M.1    Gosselin, R.2    Kitchen, S.3    Dwyre, D.M.4
  • 29
    • 84992512720 scopus 로고    scopus 로고
    • Pradaxa (dabigatran etexilate mesylate) prescribing information
    • (Accessed 2016 Apr 26).
    • Boehringer Ingelheim. Pradaxa (dabigatran etexilate mesylate) prescribing information. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. (Accessed 2016 Apr 26).
  • 30
    • 80255134514 scopus 로고    scopus 로고
    • UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma
    • Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. J Pharm Biomed Anal. 2012;58:152-6. doi: 10.1016/j.jpba.2011.09.018.
    • (2012) J Pharm Biomed Anal , vol.58 , pp. 152-156
    • Delavenne, X.1    Moracchini, J.2    Laporte, S.3    Mismetti, P.4    Basset, T.5
  • 31
    • 84880867914 scopus 로고    scopus 로고
    • Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore longitudinal study on aging: impact on renal drug dosing
    • Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore longitudinal study on aging: impact on renal drug dosing. Pharmacotherapy. 2013. doi: 10.1002/phar.1282.
    • (2013) Pharmacotherapy
    • Dowling, T.C.1    Wang, E.S.2    Ferrucci, L.3    Sorkin, J.D.4
  • 32
    • 47549086550 scopus 로고    scopus 로고
    • Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease
    • Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Clin Nephrol. 2008;70(1):10-7.
    • (2008) Clin Nephrol , vol.70 , Issue.1 , pp. 10-17
    • Hojs, R.1    Bevc, S.2    Ekart, R.3    Gorenjak, M.4    Puklavec, L.5
  • 33
    • 84904368894 scopus 로고    scopus 로고
    • A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time
    • Chin PK, Wright DF, Patterson DM, Doogue MP, Begg EJ. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol. 2014. doi: 10.1111/bcp.12364.
    • (2014) Br J Clin Pharmacol
    • Chin, P.K.1    Wright, D.F.2    Patterson, D.M.3    Doogue, M.P.4    Begg, E.J.5
  • 34
    • 79955480110 scopus 로고    scopus 로고
    • Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement
    • Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011;127(5):457-65. doi: 10.1016/j.thromres.2011.01.001.
    • (2011) Thromb Res , vol.127 , Issue.5 , pp. 457-465
    • Freyburger, G.1    Macouillard, G.2    Labrouche, S.3    Sztark, F.4
  • 35
    • 84923811544 scopus 로고    scopus 로고
    • Real-world variability in dabigatran levels in patients with atrial fibrillation
    • Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost. 2015;13(3):353-9. doi: 10.1111/jth.12823.
    • (2015) J Thromb Haemost , vol.13 , Issue.3 , pp. 353-359
    • Chan, N.C.1    Coppens, M.2    Hirsh, J.3    Ginsberg, J.S.4    Weitz, J.I.5    Vanassche, T.6
  • 36
    • 84965011923 scopus 로고    scopus 로고
    • Dabigatran etexilate; deputy office director decisional memo application 22-512
    • October 19. Accessed 30 Oct 2013).
    • US Food and Drug Administration, Center for Drug Evaluation and Research. Dabigatran etexilate; deputy office director decisional memo application 22-512. October 19, 2010. http://www.Accessdata.Fda.Gov/drugsatfda_docs/nda/2010/022512orig1s000sumr.pdf Accessed 30 Oct 2013).
    • (2010)
  • 37
    • 84859591121 scopus 로고    scopus 로고
    • Dabigatran etexilate. Advisory committee briefing document
    • August 27. Accessed 30 Oct 2013.
    • US Food and Drug Administration, Center for Drug Evaluation and Research. Dabigatran etexilate. Advisory committee briefing document, August 27, 2010. http://www.Fda.Gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf Accessed 30 Oct 2013.
    • (2010)
  • 38
    • 84930181252 scopus 로고    scopus 로고
    • Real-world variability in dabigatran levels in patients with atrial fibrillation: comment
    • Douxfils J, Chatelain B, Dogne JM, Mullier F. Real-world variability in dabigatran levels in patients with atrial fibrillation: comment. J Thromb Haemost. 2015;13(6):1166-8. doi: 10.1111/jth.12880.
    • (2015) J Thromb Haemost , vol.13 , Issue.6 , pp. 1166-1168
    • Douxfils, J.1    Chatelain, B.2    Dogne, J.M.3    Mullier, F.4
  • 39
    • 37149005153 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
    • Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59.
    • (2008) Clin Pharmacokinet , vol.47 , Issue.1 , pp. 47-59
    • Stangier, J.1    Stahle, H.2    Rathgen, K.3    Fuhr, R.4
  • 40
    • 77949421739 scopus 로고    scopus 로고
    • Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study
    • Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259-68. doi: 10.2165/11318170-000000000-000004.
    • (2010) Clin Pharmacokinet , vol.49 , Issue.4 , pp. 259-268
    • Stangier, J.1    Rathgen, K.2    Stahle, H.3    Mazur, D.4
  • 41
    • 38749131205 scopus 로고    scopus 로고
    • The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    • Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-99. doi: 10.1124/dmd.107.019083.
    • (2008) Drug Metab Dispos , vol.36 , Issue.2 , pp. 386-399
    • Blech, S.1    Ebner, T.2    Ludwig-Schwellinger, E.3    Stangier, J.4    Roth, W.5
  • 42
    • 84875938323 scopus 로고    scopus 로고
    • Genetic determinants of dabigatran plasma levels and their relation to bleeding
    • Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233.
    • (2013) Circulation , vol.127 , Issue.13 , pp. 1404-1412
    • Pare, G.1    Eriksson, N.2    Lehr, T.3    Connolly, S.4    Eikelboom, J.5    Ezekowitz, M.D.6
  • 43
    • 79958077792 scopus 로고    scopus 로고
    • Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
    • Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326-43. doi: 10.1007/s11239-011-0561-1.
    • (2011) J Thromb Thrombolysis , vol.31 , Issue.3 , pp. 326-343
    • Nutescu, E.1    Chuatrisorn, I.2    Hellenbart, E.3
  • 44
    • 84860548394 scopus 로고    scopus 로고
    • Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy
    • Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012;137(4):572-4. doi: 10.1309/AJCPAU7OQM0SRPZQ.
    • (2012) Am J Clin Pathol , vol.137 , Issue.4 , pp. 572-574
    • Avecilla, S.T.1    Ferrell, C.2    Chandler, W.L.3    Reyes, M.4
  • 45
    • 84859788384 scopus 로고    scopus 로고
    • Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice
    • Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012;107(5):838-47. doi: 10.1160/TH11-10-0718.
    • (2012) Thromb Haemost , vol.107 , Issue.5 , pp. 838-847
    • Huisman, M.V.1    Lip, G.Y.2    Diener, H.C.3    Brueckmann, M.4    Ryn, J.5    Clemens, A.6
  • 46
    • 50449091991 scopus 로고    scopus 로고
    • Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function
    • Spruill WJ, Wade WE, Cobb 3rd HH. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother. 2008;6(3):153-60. doi: 10.1016/j.amjopharm.2008.07.002.
    • (2008) Am J Geriatr Pharmacother , vol.6 , Issue.3 , pp. 153-160
    • Spruill, W.J.1    Wade, W.E.2    Cobb, H.H.3
  • 47
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
    • (1976) Nephron , vol.16 , Issue.1 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2
  • 48
    • 84880393661 scopus 로고    scopus 로고
    • Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital
    • Chin P, Vella-Brincat J, Walker S, Barclay M, Begg E. Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Intern Med J. 2013. doi: 10.1111/imj.12170.
    • (2013) Intern Med J
    • Chin, P.1    Vella-Brincat, J.2    Walker, S.3    Barclay, M.4    Begg, E.5
  • 49
    • 84877692612 scopus 로고    scopus 로고
    • Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly
    • Hellden A, Odar-Cederlof I, Nilsson G, Sjoviker S, Soderstrom A, Euler M, et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open. 2013;3(4):e002686. doi: 10.1136/bmjopen-2013-002686.
    • (2013) BMJ Open , vol.3 , Issue.4 , pp. e002686
    • Hellden, A.1    Odar-Cederlof, I.2    Nilsson, G.3    Sjoviker, S.4    Soderstrom, A.5    Euler, M.6
  • 50
    • 84930187338 scopus 로고    scopus 로고
    • Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays
    • Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Ronquist-Nii Y, Pohanka A, et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost. 2015;113(4):862-9. doi: 10.1160/TH14-09-0808.
    • (2015) Thromb Haemost , vol.113 , Issue.4 , pp. 862-869
    • Douxfils, J.1    Lessire, S.2    Dincq, A.S.3    Hjemdahl, P.4    Ronquist-Nii, Y.5    Pohanka, A.6
  • 51
    • 84877070596 scopus 로고    scopus 로고
    • In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban
    • He S, Wallen H, Bark N, Blomback M. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. J Thromb Thrombolysis. 2013;35(2):131-9. doi: 10.1007/s11239-012-0791-x.
    • (2013) J Thromb Thrombolysis , vol.35 , Issue.2 , pp. 131-139
    • He, S.1    Wallen, H.2    Bark, N.3    Blomback, M.4
  • 52
    • 84883227194 scopus 로고    scopus 로고
    • Dabigatran monitoring made simple?
    • Eikelboom JW, Weitz JI. Dabigatran monitoring made simple? Thromb Haemost. 2013;110(3):393-5. doi: 10.1160/TH13-07-0576.
    • (2013) Thromb Haemost , vol.110 , Issue.3 , pp. 393-395
    • Eikelboom, J.W.1    Weitz, J.I.2
  • 53
    • 84860528205 scopus 로고    scopus 로고
    • Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate
    • Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012;107(5):985-97. doi: 10.1160/TH11-11-0804.
    • (2012) Thromb Haemost , vol.107 , Issue.5 , pp. 985-997
    • Douxfils, J.1    Mullier, F.2    Robert, S.3    Chatelain, C.4    Chatelain, B.5    Dogne, J.M.6
  • 54
    • 79954534386 scopus 로고    scopus 로고
    • Laboratory assessment of new anticoagulants
    • Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49(5):761-72. doi: 10.1515/CCLM.2011.134.
    • (2011) Clin Chem Lab Med , vol.49 , Issue.5 , pp. 761-772
    • Samama, M.M.1    Guinet, C.2
  • 55
    • 84856593171 scopus 로고    scopus 로고
    • Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
    • Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23(2):138-43. doi: 10.1097/MBC.0b013e32834f1b0c.
    • (2012) Blood Coagul Fibrinolysis , vol.23 , Issue.2 , pp. 138-143
    • Stangier, J.1    Feuring, M.2
  • 56
    • 84937203350 scopus 로고    scopus 로고
    • An idea for a mid to long term strategy for Pradaxa, showing EMA range comparisons
    • [Cited 15 March 2016].
    • Boehringer Ingelheim. An idea for a mid to long term strategy for Pradaxa, showing EMA range comparisons. 2014. Available from: http://journals.bmj.com/site/bmj/dabigatran/compared_ema.pdf [Cited 15 March 2016].
    • (2014)
  • 57
    • 84867357013 scopus 로고    scopus 로고
    • Perspective on dabigatran etexilate dosing - why not follow standard pharmacological principles?
    • Chin PK, Vella-Brincat JW, Barclay ML, Begg EJ. Perspective on dabigatran etexilate dosing - why not follow standard pharmacological principles? Br J Clin Pharmacol. 2012. doi: 10.1111/j.1365-2125.2012.04266.x.
    • (2012) Br J Clin Pharmacol
    • Chin, P.K.1    Vella-Brincat, J.W.2    Barclay, M.L.3    Begg, E.J.4
  • 58
    • 84855876269 scopus 로고    scopus 로고
    • A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk
    • Rosencher N, Albaladejo P. A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk. Expert Opin Pharmacother. 2012;13(2):217-26. doi: 10.1517/14656566.2012.648614.
    • (2012) Expert Opin Pharmacother , vol.13 , Issue.2 , pp. 217-226
    • Rosencher, N.1    Albaladejo, P.2
  • 59
    • 84904634733 scopus 로고    scopus 로고
    • how the drug company withheld important analyses
    • Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ. 2014;349:g4670. doi: http://dx.doi.org/10.1136/bmj.g4670.
    • (2014) BMJ. , vol.349 , pp. g4670
    • Cohen, D.D.1
  • 60
    • 84937250263 scopus 로고    scopus 로고
    • Dose tailoring of dabigatran etexilate: obvious or excessive?
    • Douxfils J, Mullier F, Dogne JM. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015;14(8):1283-9. doi: 10.1517/14740338.2015.1049995.
    • (2015) Expert Opin Drug Saf , vol.14 , Issue.8 , pp. 1283-1289
    • Douxfils, J.1    Mullier, F.2    Dogne, J.M.3
  • 61
    • 77955994775 scopus 로고    scopus 로고
    • Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity
    • Ebner T, Wagner K, Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010;38(9):1567-75. doi: 10.1124/dmd.110.033696.
    • (2010) Drug Metab Dispos , vol.38 , Issue.9 , pp. 1567-1575
    • Ebner, T.1    Wagner, K.2    Wienen, W.3
  • 62
    • 0025885499 scopus 로고
    • The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions
    • Herd B, Wynne H, Wright P, James O, Woodhouse K. The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions. Br J Clin Pharmacol. 1991;32(6):768-70.
    • (1991) Br J Clin Pharmacol , vol.32 , Issue.6 , pp. 768-770
    • Herd, B.1    Wynne, H.2    Wright, P.3    James, O.4    Woodhouse, K.5
  • 63
    • 74549132748 scopus 로고    scopus 로고
    • Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system
    • Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev. 2010;42(1):209-24. doi: 10.3109/03602530903209288.
    • (2010) Drug Metab Rev , vol.42 , Issue.1 , pp. 209-224
    • Court, M.H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.